NEW YORK, September 21, 2018 /PRNewswire/ --
According to a report published by Allied Market Research, the global cancer therapeutics market was valued at
USD 81 Billion in 2016 and is expected to reach about USD 179 Billion
by 2023 while growing at a compound annual growth rate (CAGR) of 11.9%. Demand for cancer therapy increases as the number of
people who have cancer is rising rapidly. The report indicated that the market is segmented based on application, top-selling
drugs, and region. Traditional cancer therapeutics include chemotherapy and oncology drugs treatment. However, high cost of
oncology drug development may restrain the growth of oncology drugs treatment market. Regen BioPharma, Inc. (OTC: RGBP),
Celldex Therapeutics, Inc. (NASDAQ: CLDX), Onconova Therapeutics, Inc. (NASDAQ: ONTX), aTyr Pharma, Inc. (NASDAQ: LIFE), OncoSec
Medical Incorporated (NASDAQ: ONCS)
Cancer immunotherapy has emerged as a new treatment for cancer. According to research from Grand View Research, the
global cancer immunotherapy market size was valued at USD 40.7 Billion in 2016. Rising R&D in
cancer immunotherapy and increases in the number of approvals for new immune therapeutic drugs are expected to drive the
immunotherapy market. New immunotherapeutic options include immunomodulators and CAR-T cell therapy, which are in the pipeline
and are being tested for their ability to provide better cancer treatment. The report indicated most of the cancer immunotherapy
drugs have been used in the treatment of non-small cell lung cancer, breast cancer, and prostate cancer.
Regen BioPharma, Inc. (OTCQB: RGBP) earlier this month announced breaking news that it, "has identified
a series of small molecule drugs that inhibit NR2F6. Regen's screening process demonstrated that its recently-identified, novel
chemical compounds appear to inhibit NR2F6 and thus can potentially be developed for treating cancer.
The NR2F6 nuclear receptor has been identified as a potentially important immune cell inhibitor (an immune
checkpoint), which may lead to developing therapies for treating cancers. Therapies that manipulate NR2F6 also show potential to
act as cancer stem cell differentiators, transforming cancer stem cells into normal cells.
The NR2F6 program at Regen aims to identify antagonists of NR2F6 in order to unleash the cancer-killing potential
of a patient's own immune system as well as identify agonists which should suppress the immune system in diseases where the
immune system is over-activated, such as autoimmunity.
"We have identified a handful of compounds, representing three different structural classes, that inhibit NR2F6 in
our primary screening assay," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. "They
exhibited a dose-dependent inhibitory effect on NR2F6 without cytotoxicity. Our next steps will focus on determining what effect
they have on human immune cells."
David Koos, Ph.D., Chairman & CEO of Regen BioPharma Inc. added, "This is
exciting for Regen to reach this point in its goal for developing therapies that treat cancer. These compounds should provide us
the basis to further refine our screening for successful antagonists in the development of immunologically-based cancer
therapies."
Correction: Regen BioPharma previously disclosed, in error, that "inhibiting NR2F6 is believed to provide potential
therapies for treating autoimmunity." The statement should read: "Activating NR2F6 potentially leads to inhibiting the immune
system and should lead to therapies for treating autoimmunity diseases such as lupus."
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is developing targeted therapeutics to address devastating
diseases for which available treatments are inadequate. The Company's pipeline includes immunotherapies and other targeted
biologics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or
directly inhibit tumors to treat specific types of cancer or other diseases. Last month, the Company reported business and
financial highlights for the second quarter ended June 30th, 2018. Cash, cash
equivalents and marketable securities as of June 30th, 2018 were USD 114.0 Million compared to USD 123.2 Million as of March 31st, 2018. Research and development (R&D) expenses were USD 21.4
Million in the second quarter of 2018 and USD 43.3 Million for the six months ended
June 30th , 2018, compared to USD 25.0 Million and
USD 50.8 Million for the comparable periods in 2017.
Onconova Therapeutics, Inc. (NASDAQ: ONTX) is a Phase 3-stage biopharmaceutical company focused on
discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic
Syndromes (MDS). In late August, the Company announced that its commercial partner, Pint Pharma GmbH, will assist in expanding
access to clinical trials studying rigosertib, a novel and targeted anti-cancer compound currently in a Phase 3 study for the
treatment of MDS, to several selected sites across South America. Pint Pharma is a
European-based pharmaceutical company focused on the development, registration and commercialization of specialty-based
treatments for the Latin American market and has successfully participated in clinical trials for hematological cancers.
aTyr Pharma, Inc. (NASDAQ: LIFE) is a biotherapeutics company engaged in the discovery and development of
innovative medicines based on novel immunological pathways. Last month, the Company announced operating results for the second
quarter ended June 30th, 2018. In June 2018, aTyr
announced results of its Phase 1, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability,
immunogenicity and pharmacokinetics (PK) of intravenous ATYR1923 in 36 healthy volunteers. In the fourth quarter of 2018, aTyr
plans to initiate a Phase 1b/2a multiple-ascending dose, placebo-controlled, first-in-patient study
with ATYR1923 for the treatment of patients with immune-mediated interstitial lung disease. Research and development expenses
were USD 6.5 Million and USD 8.4 Million for the three months ended
June 30th, 2018 and 2017, respectively. Research and development expenses were
USD 12.6 Million and USD 17.6 Million for the six months ended
June 30th , 2018 and 2017, respectively.
OncoSec Medical Incorporated (NASDAQ: ONCS) is a clinical-stage biotechnology company focused on developing
cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Earlier this
month, the Company announced that it has secured a USD 15 Million investment from Alpha Holdings,
Inc. as part of a value-focused, fundamental strategic investment centered on the clinical development of OncoSec's lead
immunotherapy product candidate, TAVO (tavokinogene telseplasmid). TAVO enables the intratumoral delivery of DNA-based
interleukin-12 (IL-12), a naturally occurring protein with powerful immune-stimulating functions. Alpha Holdings is a
leading Korean company engaged in the design, development, service and manufacture of system semiconductors, as well as the
development of biotechnologies and thermal compound materials. Since 2002, Alpha Holdings has successfully carried out many
projects as a major partner of Samsung Advanced Foundry Eco-system (SAFE) of Samsung Electronics.
Subscribe Now - Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in
Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and
Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media,
FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination,
branding, marketing and advertising for third parties for corporate news and original content through our unique media platform
that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial
Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do
not undertake any activities that would require such registration. The information provided
on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided
[exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into
media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials
for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the
information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting
high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com
does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along
with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our
unique financial newswire and media platform. For Regen Biopharma, Inc. financial news dissemination and pr services,
FinancialBuzz.com expects to be compensated five thousand dollars by the company. Our fees may be either a flat cash
sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The
securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the
conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for
financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or
continue to post information about any companies the information contained herein is not intended to be used as the basis for
investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is
not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for
any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other
materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of
their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance,
and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound
by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com
constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment
strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is
solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives,
other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and
legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless
of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be
reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please
visit: http://www.financialbuzz.com.
For further information:
http://www.FinancialBuzz.com
Media Contact:
info@financialbuzz.com
+1-877-601-1879
SOURCE FinancialBuzz.com